Close

Pre-Open Stock Movers 08/04: (BYSI) (CERS) (GBT) Higher; (ZY) (TELL) (LPSN) Lower (more...)

August 4, 2021 9:28 AM EDT

Pre-Open Stock Movers:

BeyondSpring (NASDAQ: BYSI) 207% HIGHER; announced today the positive topline data of DUBLIN-3 registrational trial in plinabulin in combination with docetaxel to treat 2nd and 3rd line NSCLC (EGFR wild type) compared to docetaxel alone (n=559). Plinabulin is a first-in-class, selective immunomodulating microtubule-binding agent (SIMBA), which is a potent antigen presenting cell (APC) inducer. The data released today showed that compared to docetaxel alone, the combination met the primary endpoint of increasing overall survival (mean OS, p = 0.03; OS log rank, p <0.04) and met key secondary endpoints, including significantly improving ORR, PFS and 24- and 36-month OS rates, and significant reduction in the incidence of Grade 4 neutropenia.

Zymergen (NASDAQ: ZY) 77% LOWER; no longer expects product revenue in 2021, announces CEO transition.

Tellurian Inc. (Nasdaq: TELL) 15.1% LOWER; announced that it has priced a public offering of 35,000,000 shares of its common stock for total gross proceeds to Tellurian (before underwriters compensation and estimated expenses) of $105 million.

Cerus (NASDAQ: CERS) 13.5% HIGHER; reported Q2 EPS of ($0.09), in-line with the analyst estimate of ($0.09). Revenue for the quarter came in at $37.7 million versus the consensus estimate of $31.48 million. Cerus sees FY2021 revenue of $118-122 million, versus the consensus of $134.8 million.

Global Blood Therapeutics (NASDAQ: GBT) 13.5% HIGHER; reported Q2 EPS of ($1.12), $0.07 better than the analyst estimate of ($1.19). Revenue for the quarter came in at $47.6 million versus the consensus estimate of $43.84 million.

Landmark Infrastructure Partners LP (NASDAQ: LMRK) 12.5% HIGHER; Melody Investment Advisors LP, an alternative asset manager focused on mission-critical communications infrastructure, announced today that it has submitted a proposal to purchase 100% of the assets currently owned by Landmark Infrastructure Partners LP (NASDAQ: LMRK) through one or a series of transactions that would result in holders of Landmark's common units receiving $16.25 per Landmark common unit in cash.

LivePerson (NASDAQ: LPSN) 12.4% LOWER; reported Q2 GAAP EPS of ($0.31), which may not compare to the analyst estimate of ($0.13). Revenue for the quarter came in at $119.6 million versus the consensus estimate of $113.3 million. LivePerson sees Q3 2021 revenue of $117-119 million, versus the consensus of $117.92 million. LivePerson sees FY2021 revenue of $460-471 million, versus the consensus of $465.33 million.

Tupperware Brands (NYSE: TUP) 9.5% HIGHER; reported Q2 EPS of $0.95, $0.38 better than the analyst estimate of $0.57. Revenue for the quarter came in at $464.7 million versus the consensus estimate of $460.2 million.

OraSure Technologies (NASDAQ: OSUR) 8% LOWER; reported Q2 EPS of ($0.02), $0.06 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $57.6 million versus the consensus estimate of $56.69 million. OraSure Technologies sees Q3 2021 revenue of $45-50 million, versus the consensus of $67.9 million. OraSure Technologies sees FY2021 revenue of $230 million, versus the consensus of $287.63 million.

InVitae (NYSE: NVTA) 8% HIGHER; reported Q2 EPS of ($0.85), $0.20 worse than the analyst estimate of ($0.65). Revenue for the quarter came in at $116.3 million versus the consensus estimate of $108.3 million. InVitae sees FY2021 revenue of $475-500 million, versus the consensus of $463 million.

MGM Growth Properties LLC (NYSE: MGP) 7.9% HIGHER; VICI Properties Inc. (NYSE: VICI) (VICI Properties or VICI), MGM Growth Properties LLC (NYSE: MGP) (MGP) and MGM Resorts International (NYSE: MGM) (MGM Resorts), MGPs controlling shareholder, announced today that they have entered into a definitive agreement (the Master Transaction Agreement) pursuant to which VICI Properties will acquire MGP for total consideration of $17.2 billion, inclusive of the assumption of approximately $5.7 billion of debt. Upon completion of the merger, VICI will have an estimated enterprise value of $45 billion, firmly solidifying VICIs position as the largest experiential net lease REIT while also advancing VICIs strategic goals of portfolio enhancement and diversification.

Horizon Therapeutics (NASDAQ: HZNP) 6.8% HIGHER; reported Q2 EPS of $1.62, $0.74 better than the analyst estimate of $0.88. Revenue for the quarter came in at $832.5 million versus the consensus estimate of $685.03 million. Horizon Therapeutics sees FY2021 revenue of $3.025-3.125 billion, versus the consensus of $2.81 billion.

Paycom Software (NYSE: PAYC) 6.7% HIGHER; reported Q2 EPS of $0.97, $0.13 better than the analyst estimate of $0.84. Revenue for the quarter came in at $242.1 million versus the consensus estimate of $232.12 million. Paycom Software sees FY2021 revenue of $1.036-1.038 billion, versus the consensus of $1.02 billion.

Endo International plc (NASDAQ: ENDP) 6.4% HIGHER; today announced that its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, "Endo") have executed a definitive Settlement Agreement and Release (the "Settlement Agreement") resolving an opioid-related case originally captioned as Staubus, et al. v. Purdue Pharma, L.P., et al., Case No. C-41916, in the Circuit Court for Sullivan County, Tennessee.

Calavo Growers (Nasdaq: CVGW) 6% LOWER; announced today that after an initial review of its third quarter 2021 operating results, the Company now expects revenue to be between $275 million and $285 million, near the low end of its previously announced range, while adjusted EBITDA (a non-GAAP financial measure) is expected to be in the range of $0 to $2 million, below its previously announced range of $11 million to $15 million. Calavo’s third quarter 2021 results will be reported on September 8, 2021, and the Company will hold its earnings call the same day.

Activision Blizzard (NASDAQ: ATVI) 5.8% HIGHER; reported Q2 EPS of $1.20, $0.46 better than the analyst estimate of $0.74. Net bookings for the quarter came in at $1.921 billion versus the consensus estimate of $1.89 billion. Activision Blizzard sees Q3 2021 EPS of $0.75, versus the consensus of $0.74. Activision Blizzard sees Q3 2021 net bookings of $1.85 billion, versus the consensus of $1.8 billion. Activision Blizzard sees FY2021 EPS of $3.54, versus the consensus of $3.77. Activision Blizzard sees FY net bookings of $8.65 billion, versus the consensus of $8.768 billion.

CVS Health (NYSE: CVS) 4.6% LOWER; reported Q2 EPS of $2.42, $0.36 better than the analyst estimate of $2.06. Revenue for the quarter came in at $72.6 billion versus the consensus estimate of $70.11 billion. CVS Health sees FY2021 EPS of $7.70-$7.80, versus the consensus of $7.66.

General Motors (NYSE: GM) 4.2% LOWER; reported Q2 EPS of $1.97, $0.63 better than the analyst estimate of $1.34. Revenue for the quarter came in at $34.2 billion versus the consensus estimate of $29.11 billion. General Motors sees FY2021 EPS of $5.40-$6.40, versus the consensus of $6.42.

Match Group (NASDAQ: MTCH) 4% LOWER; reported Q2 EPS of $0.46, $0.05 worse than the analyst estimate of $0.51. Revenue for the quarter came in at $707.8 million versus the consensus estimate of $689.33 million. Match Group sees Q3 2021 revenue of $790-805 million, versus the consensus of $761 million. Match Group sees FY 2021 revenue of $2,875-2,890 million.

Match Group (NASDAQ: MTCH) 3.9% LOWER; reported Q2 EPS of $0.46, $0.05 worse than the analyst estimate of $0.51. Revenue for the quarter came in at $707.8 million versus the consensus estimate of $689.33 million. Match Group sees Q3 2021 revenue of $790-805 million, versus the consensus of $761 million.

RingCentral, Inc. (NYSE: RNG) 3% HIGHER; reported Q2 EPS of $0.32, $0.04 better than the analyst estimate of $0.28. Revenue for the quarter came in at $379 million versus the consensus estimate of $359.51 million. RingCentral, Inc. sees FY2021 EPS of $1.28-$1.30, versus the consensus of $1.26. RingCentral, Inc. sees FY2021 revenue of $1.539-1.545 billion, versus the consensus of $1.51 billion.

Cardlytics (NASDAQ: CDLX) 2% LOWER; reported Q2 EPS of ($0.39), in-line with the analyst estimate of ($0.39). Revenue for the quarter came in at $58.9 million versus the consensus estimate of $62.81 million. Cardlytics sees Q3 2021 revenue of $57-66 million, versus the consensus of $71 million.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Earnings, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers